President and CEO
Bob has been President & COO for Senior Scientific, LLC since February 2015 and has led the company through the recent restructuring and recapitalization efforts. Previous employment experience includes Pres/GM for Silicon Biosystems and a career in marketing and sales management with more than 25 years experience in the computer, life science and medical diagnostics industries, e.g. Vice President Marketing and Sales for Nanogen, Inc., Senior Vice President of Marketing and Business Development at Gene Logic, and General Manager, Life Sciences at IGEN International, Inc. Mr. Proulx holds an M.A. and B.A. from The State University of New York at Albany and an Executive MBA from the Penn State Smeal College of Business.
Chief Financial Officer
Brian has served as a financial executive in high growth companies for over twenty years, within and outside of the life sciences industry. From 2011 to 2016, Mr. Conn served as Chief Financial Officer for Verdezyne Inc., raising $170 million in equity, debt, project finance and government incentives. Prior to Verdezyne, Mr. Conn held executive positions, including Chief Financial Officer with Chemicon International, Serologicals Corporation, Millipore Corporation and MicroIslet Inc. He has extensive experience with capital transactions, mergers and acquisitions, commercial operations and startups. Mr. Conn holds a Bachelor of Science degree in Finance from Arizona State University.
Vice President R&D
Dr. Paciotti is an accomplished scientist in tumor biology and the development of nanotechnologies for the early diagnosis and treatment of cancer. Prior to joining Imagion Biosystems Dr. Paciotti had developed a gold nanoparticle-based therapeutic. Currently he leads Imagion’s team in developing the MagSense™ technology for the detection of early stage and disseminated cancers. Complimenting his scientific credentials is a 15-year record of bringing complex nanomedicines through the regulatory process including cGMP manufacturing and analytical program development, toxicology and IND (IDE) submission. Dr. Paciotti holds multiple patents in nanotechnology for use in oncology, drug delivery, cancer detection, human monoclonal antibody generation, infectious disease and biodefense. Dr. Paciotti received his PhD from the University of Maryland at College Park.
Vice President Clinical Research
Dr Bischoff adds a wealth of relevant experience in oncology product commercialisation to the leadership team at Imagion Biosystems. Her accomplishments include scientific development, regulatory submission and successful commercialisation of molecular diagnostics for Biocept. She has led numerous productive collaborative studies, including the NIFTY NIH Fetal Cell Study, composed of individuals from academic, pharmaceutical and biotech organisations.
She is widely recognised in the fields of rare cancer cell detection, molecular cytogenetics, diagnostic assay development and validation. Dr Bischoff holds a PhD from the University of Texas Graduate School of Biological Sciences, Houston. Her doctoral thesis led to the discovery of the p53 tumor suppressor gene and the emergence of a productive new avenue of global cancer research.
Board of Directors
Retired VP & CTO, GE Medical Imaging
Mike has over 36 years of experience in healthcare technology, focused on diagnostic imaging having served as Vice President and Chief Technology Officer for GE Healthcare. As the Global Technology Leader of Imaging Technologies at GE Global Research, he led the research for X-Ray, CT, MRI, Ultrasound, Nuclear Medicine, PET and Optical Imaging, and the research associated with computer visualization/image analysis and superconducting systems. In 2008 Mike was elected to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows, for his significant contributions to the medical and biological engineering field. Mr. Harsh is a co-founder of Terapede Systems.
Chair, Dept Imaging Physics, MD Anderson
Dr. Hazle is a medical physicist with over 25 years of academic experience. He is board-certified and licensed in Texas for both therapeutic and diagnostic medical physics. His primary research interests are image-guided therapy, pre-clinical imaging and novel early detection technologies. Dr. Hazle has been the Director of the NCI funded Small Animal Cancer Imaging Research Facility for 15 years and was the Director of the NCI funded Experimental Cancer Imaging Research Program from 2008-2012. Dr. Hazle serves on multiple institutional committees, engages as a medical imaging expert with industry partners, and is currently a journal reviewer for six peer reviewed scientific journals. He is a past President of the American Association of Physicists in Medicine and the Commission for Accreditation of Medical Physics Education Programs. Dr. Hazle also holds the Bernard W. Biedenharn Chair in Cancer Research and has a faculty appointment with The University of Texas Graduate School of Biomedical Sciences.
David is currently CEO at Nanomix, a point-of-care diagnostic medical device company. David is a financial and operating executive with over 35 years of international experience in life sciences and technology companies including IDEC Pharmaceuticals, Matrix Pharmaceutical, Nanogen, and MIPS Computer Systems. His experience over 15 years in the diagnostics arena has led numerous new product efforts from concept to market launch. Mr. Ludvigson has concluded many successful strategic transactions including multiple acquisitions, corporate partnerships, technology and intellectual property licensing agreements, and OEM relationships and his financing experience includes venture capital, corporate, mezzanine, lease, bank credit line, LBO, IPO and secondary public sources.
MANAGING DIRECTOR, DIAGNOSTIC TECHNOLOGY
Mark has over 30 years of experience in the medical diagnostics and life science industry. Much of this time has been specific to international business development, strategic planning and introduction of new technology. Through Diagnostic Technology, a company he founded, he has been responsible for the development and introduction of a number of innovative technology platforms and technologies into mainstream healthcare use, including HPV DNA testing for cervical cancer screening and the molecular monitoring for both viral infections and cancer treatments. He holds an Adjunct Senior Lectures position at the School of Biotechnology and Biomolecular Science, University of NSW where he has collaborated on a number of research projects related to biosynthetic pathways in bacteria.
CORPORATE ATTORNEY AND BUSINESS MANAGER
Jovanka is an Australian legal practitioner with expertise in intellectual property law, corporate law, and corporate governance. She holds the Officer role of corporate Secretary for Imagion Biosystems Ltd., and serves Australian scientific development organizations in an expert capacity on matters relating to corporate law, business operations, intellectual property development, and regulatory compliance.
MANAGING DIRECTOR, ANDHealth
Ms Le Grice has more than 15 years of experience in healthcare and technology markets spanning venture capital, capital raising and corporate governance for Australian listed companies and non-profit organisations. She is currently Managing Director of ANDHealth, a unique industry-led non-profit organisation focused on strengthening the Australian digital health ecosystem and de-risking innovations in digital health.
Prior to founding ANDHealth, Ms Le Grice was an Investment Director with leading Australian healthcare venture capital firm BioScience Managers, where she was responsible for managing significant transactions in the health technology and digital health sectors, resulting in more than A$65m of private and public equity raisings. This included IPOs on the Australian Securities Exchange and the UK Alternative Investments Market, in addition to participating in deal origination, due diligence and negotiation for two funds totaling A$96m under management.